NEW YORK (TheStreet) -- Juno Therapeutics (JUNO) stock is slumping by 3.51% to $50.01 in after-hours trading on Tuesday, after the company reported its 2015 third quarter earnings results after the market close today. 

The biopharmaceutical company posted a loss of 53 cents per share for the most recent quarter, up from a loss of $2.68 per share for the year ago period. Analysts surveyed by Thomson Reuters had forecast for a loss of 41 cents per share.

Revenue was $1.6 million for the most recent quarter, short of analysts' forecast for $6.51 million. 

"We continue to make progress in the clinic and building our capabilities," CEO Hans Bishop said in a statement. "We completed engineering runs at our manufacturing facility in Bothell. We also continued building out our internal research organization and integrated our two acquisitions."

Image placeholder title

JUNO

data by

YCharts

Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of Jim Cramer, TheStreet or any of its contributors.